Rubella virus (RV) virions contain two envelope glycoproteins (El and E2) and a capsid protein (C). Noninfectious RV-like particles (VLPs) containing three structural proteins were expressed in a BHK cell line (BHK-24S) by using an inducible promoter. These VLPs were found to resemble RV virions in terms of their size, their morphology, and some biological activities. In immunoblotting studies, VLPs were found to bind similarly to native RV virions with 10 of a panel of 12 RV-specific murine monoclonal antibodies. Immunization of mice with VLPs induced specific antibody responses against RV structural proteins as well as virus-neutralizing and hemagglutination-inhibiting antibodies. After immunization of mice with VLPs, in vitro challenge of isolated lymphocytes with inactivated RV and individual RV structural proteins stimulated proliferation. Our data suggest the possibility of using VLPs as immunogens for serodiagnostic assays and RV vaccines.
Rubella virus (RV), a member of the Togavirus family (20) , is the etiological agent of German measles in humans, the only known host. RV infection during pregnancy may result in spontaneous abortion and congenital defects (1) . Vaccination with live, attenuated virus has been successful in reducing the incidence of congenital rubella syndrome (29) . However, rubella-associated arthritis and the consequence of viral persistence in vaccinees resulting from RV vaccination remain major medical concerns (3) . A new approach using RV-like particles (VLPs) is an alternative to conventional attenuated RV vaccines, since these particles contain all of the RV structural proteins and are nonreplicating.
RV contains three major structural proteins, capsid protein (C, 33 kDa) and the E2 (42 to 47 kDa) and El (57 kDa) glycoproteins (22) , that are proteolytically cleaved from a polyprotein precursor translated from a 24S subgenomic RNA in RV-infected cells (23) . E2 and El are membrane glycoproteins located on the virion exterior (22, 38) , and the capsid protein is associated with the genomic RNA, forming the nucleocapsid (22) . Glycoprotein El is the dominant surface molecule of RV (5, 40) . Virus-neutralizing (VN) and hemagglutination (HA) epitopes have been allocated to El by using murine monoclonal antibodies (MAbs) (4, 11, 35, 39, 40) . Studies of the immune response to RV infection in humans have indicated that El is the major target antigen as compared with E2 and C (5, 25, 42) . Genetically engineered RV structural proteins have been produced in Escherichia coli (4, 36, 41) , insect cells (33) , and mammalian cells (2, 13, 30, 32) . However, the antigenicity of expressed proteins is either lost or greatly reduced after purification (17, 36) . Furthermore, the capacity of expressed El protein to elicit antibody responses in animals is dependent on the native conformation of the El protein (30, 36) .
Although it is known that RV-immune individuals have T cells that proliferate in vitro in the presence of RV, only recently have the specific determinants of this response come under study. Cell-mediated immunodominant domains have been identified within all three structural proteins (5, 6, 18, 19, (24) (25) (26) . These domains stimulate major histocompatibility complex class II-restricted CD4+ helper T cells (24, 26, 27) or class I-restricted CD8+ cytotoxic T cells (18) in human populations. It appears that a practical approach to produce an efficacious rubella vaccine is to prepare genetically engineered VLPs that contain both linear and conformation-dependent epitopes of RV structural proteins (C, E2, and El).
It has been proposed that immunogenicity can be achieved by presenting antigens on a polyvalent particle structure. This concept led to the development of chimeric virus (7, 15, 21) , VLPs (12) , or immunostimulating complexes (34) , in which multiple copies of antigen are integrated in a particulate form. These particles have been found to induce both humoral and cell-mediated immune responses, including VN antibodies (12, 15, 21) , T helper cells, or cytotoxic T lymphocytes (12, 15, 34) ing to the RV cDNAs used for transfection: BHK-C, BHK-E2E1, and BHK-24S.
Expression of RV structural proteins and assembly of VLPs in stable transformed cells. The expression of RV structural proteins from stable transformed cell lines was analyzed by immunoblotting (37) . Monolayers of stable transformed cells were incubated with medium containing 30 ,uM zinc sulfate for 12 h to induce the expression of RV structural proteins from the promoter. Samples from medium and cell lysates were collected and directly subjected to sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE). Separated proteins were transferred to nitrocellulose membranes and probed with human anti-RV serum. In BHK-C cells, an intracellular protein species with molecular size of 34 kDa was observed ( Fig. 2A , lanes C). This protein may represent the capsid protein of RV. In BHK-E2E1 cells, protein species corresponding to the endoplasmic reticulum and Golgi forms of RV E2 (13) and El glycoproteins were found in the cell lysate but not in the medium ( Fig. 2A , lanes E2E1), indicating that the E2E1 polyprotein precursor was synthesized and proteolytically processed to give rise to E2 and El proteins. In BHK-24S cells, protein species corresponding to the C, E2, and El proteins of RV were present in the cell lysate as well as in the medium ( Fig. 2A , lanes 24S), suggesting that the integrated cDNA of 24S RNA was active in directing the synthesis of RV structural proteins and these structural proteins were released from the cells. The secretion of RV structural proteins from BHK-24S increased with time and was linear over a period of 24 h under ZnSO4 induction (Fig. 2C) .
The secretion of RV structural proteins into the medium was found to be dependent on the coexpression of C, E2, and El, suggesting that these proteins are assembled into subviral RV-infected cells (Fig. 2B, lanes 2 and 3) . In the presence of Nonidet P-40, El and E2 glycoproteins remained in the supernatant after ultracentrifugation (not shown), although trace amounts of C were found in the pellet (Fig. 2B, lane 1) (Fig. 3A) and indistinguishable in appearance, with an electron-dense core surrounded by an envelope (Fig. 3B, C , and D). These particles were located predominantly within the vacuoles in the juxtanuclear region (Fig. 3D) or cytoplasm (Fig. 3C) , which may represent the Golgi structure. Some particles were distributed in the cytoplasm (Fig. 3B) Fig. 4 , mice immunized with the VLPs produced antibodies against all three structural proteins of RV (Fig. 4, lanes 3) , as did mice immunized with RV (Fig. 4, lane 4) . Mice immunized with El protein also developed some anti-El antibody response (Fig. 4, lane 2) .
ELISA was used to quantify the antibody titers against each of the RV structural proteins, by using individual purified RV structural proteins expressed in SF9 cells infected with baculovirus recombinants (unpublished data) as antigens. In the 1 2 3 4 . i4E2   FIG. 4 . Radioimmunoprecipitation of RV structural proteins expressed in COS cells. COS cells were transfected with pCMV5-24S (13), labelled with [35 S]methionine, and lysed. RV structural proteins were recovered from cell lysates with mouse anti-RV antibodies prebound to Sepharose 4B-protein A beads as previously described (13) sera from mice immunized with VLPs, a significantly higher anti-C antibody titer was found, whereas anti-El and E2 antibody titers were slightly lower ( Table 2 ). The biological functions of these antibodies were analyzed. Sera from VLPimmunized mice displayed VN activities (Table 2) as determined by plaque reduction assays (9) . HA-inhibiting activities were also present in the sera from mice immunized with the VLPs, as well as in the sera from mice immunized with RV (Table 2 ). These results suggested that although VLPs were less active in inducing overall anti-El and E2 antibodies compared with RV, they induced the production of both VN and HA-inhibiting antibodies.
We have also determined cell-mediated immune responses against RV in VLP-immunized mice in a lymphocyte proliferation assay (5, 26) . Lymphocyte proliferative responses of mice were determined in vitro by direct stimulation of lymphocytes with UV-inactivated RV or individual RV structural proteins (C, E2, and El) purified from recombinant baculovirus-infected insect cells. Lymphocytes from VLP-immunized mice responded strongly to UV-inactivated RV as well as to the individual RV structural proteins in a dose-dependent manner (Fig. 5) .
The assembly of RV virions involves at least two major steps: encapsidation and envelopment of nucleocapsids. In RV, Incorporation of nucleocapsid into the membrane envelope to form virus particles is a poorly understood event in virus assembly. We found that in BHK-C and BHK-E2E1 cells, no RV proteins were released into the medium (Fig. 2A) . In BHK-24S cells, all three structural proteins were present in the medium as the result of subviral particle formation and egress (Fig. 2) . These data strongly suggest that the interaction between glycoproteins and the nucleocapsid is the driving force for the assembly and release of the VLPs. This interaction has been defined to occur between the cytoplasmic tail of glycoprotein El and the capsid protein. Deletion of the cytoplasmic domain of RV El abolished the delivery of the VLPs into the medium (12a).
Besides being a useful tool to study RV assembly, BHK-24S cells in which VLPs are steadily assembled and released can be used as a potential source for mass production of rubella antigens at low cost under inducing conditions. BHK-24S cells continuously produce VLPs for up to 5 days without cell lysis when 30 pLM ZnSO4 is present in the medium and for up to 1 2 month in DME/F12 (GIBCO) medium. VLPs can be harvested daily from the medium, which is replaced with fresh medium after harvesting. Depending on the methods used to quantitate the yields of the VLPs and RV from culture medium, the yield of VLPs was found to be 2 times higher than that of RV in an HA assay, 5 times higher in ELISAs using human sera, and more than 10 times higher by protein quantitation using silver staining after gel electrophoresis (data not shown). For immunogenicity studies, the VLPs were found to be significantly more active than the soluble El protein in inducing antibody responses in mice, especially for the production of VN and HA-inhibiting activity. The VLPs also evoked a cell-mediated immune response to RV and RV structural proteins. This is believed to be important in providing protec 
